9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 248

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Progression Free Survival,  Overall survival (OS),  Time to worsening of symptoms characteristic of mesothelioma, Time to worsening of pain

Interventions: Anetumab ravtansine (BAY 94-9343), Vinorelbine

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: May 31, 2017

Completion Date: July 16, 2019

Last  Posted Date: June 10, 2019

Location: La Jolla, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT02610140

Was this article helpful?
Dislike 0